Stryker Makes $400 Million Robotic Surgery Bet
Stryker invests $400M in CMR Surgical to expand into soft-tissue robotics and secure exclusive U.S. sales rights for the Versius system.
Stocks · News reference
8-K filing — STRYKER CORP (SYK)
Filed: 2026-10-06 AccNo: 0001193125-26-414956 Size: 1 MB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
ASML: A Rule Breaker Test of Lasting Leadership
ASML faces a critical test of whether its leadership can maintain success after founders Martin van den Brink and CEO Peter Wennink retired in 2024. New CEO Christophe Fouquet has raised 2026 sales forecasts to €43-45 billion, but investors must assess whether the company's founder-driven culture persists. The article examines whether post-founder leadership can sustain Rule Breaker companies, using ASML's upcoming earnings report as a key indicator.
Stryker Announces ~$400M Investment In CMR Surgical With Exclusive Option To Acquire 100%; To Be Exclusive U.S. Sales Agent For Versius Robots
BTIG Maintains Buy on Stryker, Lowers Price Target to $316
BTIG analyst Ryan Zimmerman maintains Stryker (NYSE:SYK) with a Buy and lowers the price target from $358 to $316.